• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UnitedHealthcare nod sends Uroplasty shares up 15%

UnitedHealthcare nod sends Uroplasty shares up 15%

April 6, 2011 By MassDevice staff

Uroplasty

Shares of Uroplasty Inc. (NSDQ:UPI) surged 15 percent yesterday after the company reported a slew of positive reimbursement news, including a pickup by UnitedHealthcare, the largest health insurer in the U.S.

The UnitedHealthcare decision adds its 33 million-patient roster to the more than 30 million Medicare patients already under the coverage umbrella for Uroplasty’s Urgent PC neurostimulation device to treat urinary incontinence. The Minneapolis, Minn.-based company’s UrgentPC system is a posterior tibial nerve stimulation device that, unlike competing devices from Medtronic Inc. (NYSE:MDT) and others, is minimally invasive.

President and CEO David Kaysen told MassDevice that the decisions expand the total pool of patients with private insurance coverage for the procedure to about 70 million.

Uroplasty president and CEO David Kaysen

Kaysen

"Probably the best and most important part of the UnitedHealthcare decision is that they did a really extensive and thorough review of the clinical data on PTNS," Kaysen told us. "What made us feel good is that, based on that published data, they made the decision."

UPI shares went on a tear yesterday after news of the UnitedHealthcare decision broke, rising from a $6.85 open, peaking at $7.95 before closing at $7.87 for a tidy 14.9 percent gain on the day.

Uroplasty shares rose even higher in pre-market trading, hitting $8.05 before débuting its day on Wall Street at $7.95. Shares were down slightly to $7.74 as of about 10:45 this morning.

Analysts on The Street were as upbeat as Kaysen over the news. Matt Dolan of Roth Capital Partners called his forecast of 45 new accounts for Uroplasty during the first three quarters of this year conservative, noting that “these developments are critical in supporting Uroplasty’s push to add new accounts and drive utilization.”

And Charles Haff, of Dougherty & Co. LLC in Minneapolis, noted that the favorable comparison between UrgentPC and the only other FDA-cleared neurostimulation device, Medtronic’s InterStim (which won pre-market approval from the FDA last November for fecal incontinence).

“The approval of MDT’s InterStim may fuel further adoption of Uroplasty’s Urgent PC device and present upside to our estimates in F12 and beyond,” Haff wrote, noting that his firm’s polls of doctors showed that perhaps as many as half of patients diagnosed with fecal incontinence also suffer from urinary incontinence.

The comparison makes UrgentPC a "viable alternative" for second-line treatment of urinary incontinence after first-line drug treatments have been ruled out "by being much less invasive and costly," Kaysen said.

"Typically the first line of defense is, almost universally, medications. That’s about a $3 billion dollar market for pharmaceuticals. Five or six million patients in the U.S. have tried one or more drugs," he said. "We really view our product as being for patients who’ve tried one or more drugs and stopped."

It’s been up and down for Uroplasty since late last year, when it announced a positive reimbursement decision in late November, only to disclose a negative decision less than two weeks later that sent its shares down to $4.38.

But with nine of the 13 regional Medicare carriers signed on and a 10th (which bestows UrgentPC coverage on a case-by-case basis) poised to succumb, Kaysen is upbeat that the three holdouts will come around.

"We’re meeting with those medical directors and educating them about the clinical data," he told us. "We believe at some point in time these will initiate coverage."

Filed Under: Neuromodulation/Neurostimulation, News Well, Urology, Wall Street Beat Tagged With: Uroplasty Inc.

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy